EU/3/15/1507: Orphan designation for the treatment of non-infectious uveitis

3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid


On 19 June 2015, orphan designation (EU/3/15/1507) was granted by the European Commission to Panoptes Pharma GesmbH, Austria, for 3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid for the treatment of non-infectious uveitis.

Key facts

Active substance
3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid
Medicine name
Intended use
Treatment of non-infectious uveitis
Orphan designation status
EU designation number
Date of designation

Kiora Pharmaceuticals GmbH
Reisnerstrasse 34/1
1030 Vienna
Tel. +43 664 8557 369

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

September 2023The sponsor’s name was changed from Panoptes Pharma Ges.m.b.H to Kiora Pharmaceuticals GmbH.  

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating